Leqembi included in China's commercial insurance innovative drug list
Prnewswire·2025-12-08 23:42
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China. Leqembi is the result of a long-standing collaboration between BioAr ...